Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Complete Response Letter
Fierce Pharma
FDA's response letter salvo sheds light on drug refusal process
The FDA's response letter salvo offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market.
James Waldron
,
Fraiser Kansteiner
Jul 11, 2025 10:15am
FDA rejects Capricor’s DMD cell therapy, asks for more data
Jul 11, 2025 9:18am
FDA shares more than 200 CRLs for now-approved drugs
Jul 10, 2025 10:54am
Stealth CEO questions FDA rejection of rare disease drug
May 29, 2025 2:27pm
Stealth hit by FDA rejection to twice-delayed filing
May 29, 2025 7:46am
Vanda sues FDA over months-long hearing delay
Apr 23, 2025 10:33am